AI steps in to help babies battling drug withdrawal

NCT ID NCT06303986

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Rekovar Inc. Source: ClinicalTrials.gov ↗

Summary

This study aims to collect data to develop an artificial intelligence (AI) tool for newborns with Neonatal Abstinence Syndrome (NAS), a condition caused by drug exposure before birth. Researchers will gather information from 100 babies—80 with NAS and 20 healthy babies—to train the AI to predict symptoms and automate scoring. The goal is to create a more objective monitoring system to help guide care and potentially reduce hospital stays.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL ABSTINENCE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University of New Mexico

    Albuquerque, New Mexico, 87106, United States

Conditions

Explore the condition pages connected to this study.